

XACDURO® (SULBACTAM FOR INJECTION; DURLOBACTAM FOR INJECTION) BILLING AND CODING RESOURCE

Refer to this guide for coding information when billing for XACDURO.

This guide is for general educational purposes only. It is not intended to be used as billing, coding, or reimbursement advice.

ICD-10-CM diagnosis codes for XACDURO

WHEN DESCRIBING:	CHOOSE APPROPRIATE ICD-10-CM CODE:
Hospital-acquired bacterial pneumonia due to <i>Acinetobacter baumannii</i> (HABP)	Y95 – Nosocomial condition is a medical classification as listed by WHO under the range - external causes of morbidity
	J15.61 – Pneumonia due to <i>Acinetobacter baumannii</i>
Ventilator-associated bacterial pneumonia due to <i>Acinetobacter baumannii</i> (VABP)	J95.851 – Ventilator-associated pneumonia
	B96.83 – <i>Acinetobacter baumannii</i> as the cause of diseases classified elsewhere
Resistance to antimicrobial drugs	Z16.10 – Resistance to unspecified beta lactam antibiotics
	Z16.19 – Resistance to other specified beta lactam antibiotics
	Z16.20 – Resistance to unspecified antibiotics
	Z16.24 – Resistance to multiple antibiotics
	Z16.29 – Resistance to other single specified antibiotic

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; WHO=World Health Organization.

INDICATION & USAGE

Indication

XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use is indicated in adults for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of *Acinetobacter baumannii-calcoaceticus* complex.

Limitations of Use

XACDURO is not indicated for the treatment of HABP/VABP caused by pathogens other than susceptible isolates of *Acinetobacter baumannii-calcoaceticus* complex.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XACDURO and other antibacterial drugs, XACDURO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

SELECTED IMPORTANT SAFETY INFORMATION

Contraindications: XACDURO is contraindicated in patients with a history of known severe hypersensitivity to the components of XACDURO or other beta-lactam antibacterial drugs.

Please see additional Important Safety Information throughout. Before administering, please see the accompanying Full Prescribing Information for XACDURO.

XACDURO[®]
(sulbactam for injection;
durlobactam for injection),
co-packaged for intravenous use

Additional codes for XACDURO: apply as appropriate

CODING	
Code set	Codes
NDC	<p>68547-111-10 – single-dose kit</p> <p>68547-211-20 – Sulbactam, 1-g vial</p> <p>68547-311-30 – Durllobactam, 0.5-g vial</p>
CPT	96365 – Intravenous infusion for therapy, prophylaxis, or diagnosis
ICD-10-PCS	3E03329 – Introduction of other anti-infective into peripheral vein, percutaneous approach
Revenue code	0636 – pharmacy drugs requiring detailed coding

Coverage determinations are made based on individual patient conditions and can vary depending on local payer policies. If you have questions, consult with the appropriate payer(s) regarding billing and coding and follow their guidelines.

CPT= Current Procedural Terminology; ICD-10-PCS= International Classification of Diseases, Tenth Revision, Procedure Coding System; NDC= National Drug Code.

SELECTED IMPORTANT SAFETY INFORMATION

Warnings and Precautions:

- Hypersensitivity was observed in patients treated with XACDURO in clinical trials. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before initiating therapy with XACDURO, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta lactams, and other allergens. If an allergic reaction occurs, discontinue XACDURO.

Please see additional Important Safety Information throughout. Before administering, please see the accompanying Full Prescribing Information for XACDURO.

This guide is for general educational purposes only. It is not intended to be used as billing, coding, or reimbursement advice.

Sample claim form: CMS-1500

Medicare submission for XACDURO and administration services

Site of care: **physician office**

The form is a CMS-1500 Medicare claim form. It includes sections for Patient Information, Insurance Plan Name, Dates of Current Illness, Referring Provider, and Procedures, Services, or Supplies. A yellow callout box highlights the 'D. PROCEDURES, SERVICES, OR SUPPLIES' section, which contains the text 'ENTER PROCEDURE AND CPT CODES' and 'Indicate the appropriate procedural and CPT codes'. The form also includes fields for diagnosis, charges, and provider information.



Scan this QR code to find **Medicare CMS-1500** form completion and coding instructions in **Chapter 26** of the Medicare Claims Processing Manual (Pub.100-04).

SELECTED IMPORTANT SAFETY INFORMATION

Warnings and Precautions (cont'd):

- Clostridioides difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. If CDAD is suspected or confirmed, the risk/benefit of continuing treatment with XACDURO should be assessed.
- Prescribing XACDURO in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Please see additional Important Safety Information throughout. Before administering, please see the accompanying Full Prescribing Information for XACDURO.

This guide is for general educational purposes only. It is not intended to be used as billing, coding, or reimbursement advice.

Sample claim form: CMS-1450 UB-04

Medicare submission for XACDURO and administration services

Site of care: **hospital inpatient**

42 REV. CD.	43 DESCRIPTION	44 HCPCS / RATE / HIPPS CODE	45 SERV. DATE	46 SERV. UNITS	47 TOTAL CHARGES	48 NON-COVERED CHARGES	49	
1							1	
2							2	
3							3	
4							4	
5							5	
6							6	
7							7	
8							8	
9							9	
10							10	
11							11	
12							12	
13							13	
14							14	
15							15	
16							16	
17							17	
18							18	
19							19	
20							20	
21							21	
22							22	
PAGE ____ OF ____		CREATION DATE		TOTALS				
50 PAYER NAME		51 HEALTH PLAN ID	52 REL INFO	53 ASSG BEN	54 PRIOR PAYMENTS	55 EST. AMOUNT DUE	56 NPI	
A							57	
B							OTHER	
C							PRV ID	
58 INSURED'S NAME		59 P.REL	60 INSURED'S UNIQUE ID		61 GROUP NAME	62 INSURANCE GROUP NO.		
A								
B								
C								
63 TREATMENT AUTHORIZATION CODES						65 EMPLOYER NAME		
A								
B								
C								
66 DX	67	A	B	C	D	E	F	
		J	K	L	M	N	O	
		P	Q				68	
69 ADMIT DX	70 PATIENT REASON DX	74 PRINCIPAL PROCEDURE CODE DATE		71 PPS CODE		72 ECI		
		a. OTHER PROCEDURE CODE DATE		b. OTHER PROCEDURE CODE DATE		75		
		c. OTHER PROCEDURE CODE DATE		d. OTHER PROCEDURE CODE DATE		e. OTHER PROCEDURE CODE DATE		
80 REMARKS		81CCI a		76 ATTENDING NPI		QUAL		
				LAST		FIRST		
				77 OPERATING NPI		QUAL		
				LAST		FIRST		
				78 OTHER NPI		QUAL		
				LAST		FIRST		
				79 OTHER NPI		QUAL		
				LAST		FIRST		

Enter NDC codes for XACDURO
 68547-111-10 – 1 kit in carton
 68547-211-20 – 5 in 1 vial (single dose)
 68547-311-30 – 2.5 mL in 1 vial (single-dose)

Enter appropriate diagnosis code

Enter appropriate ICD-10-PCS code for XACDURO

Scan this QR code to find Medicare CMS-1450 UB-04 form completion and coding instructions in Chapter 25 of the Medicare Claims Processing Manual (Pub.100-04).



SELECTED IMPORTANT SAFETY INFORMATION

Adverse Reactions: The most common adverse reactions reported in >10% of patients treated with XACDURO were liver test abnormalities (19%), diarrhea (17%), anemia (13%), and hypokalemia (12%).

Before administering, please see the accompanying Full Prescribing Information for XACDURO.



XACDURO® is marketed by Innoviva Specialty Therapeutics, Inc. © 2023 Innoviva Specialty Therapeutics™ All rights reserved. Printed in USA | PM-SUL-00052-US | 10/23

This guide is for general educational purposes only. It is not intended to be used as billing, coding, or reimbursement advice.